AI Engines For more Details: Perplexity Kagi Labs You
Enhancement of Imaging: The primary purpose of iopromide is to improve the visibility of structures and organs during diagnostic imaging procedures. It works by altering the density of the tissues it flows through, making them more visible on X-ray or CT images. This enhancement allows healthcare providers to obtain clearer and more detailed images for the diagnosis and management of various medical conditions.
Intravenous Administration: Iopromide is typically administered intravenously, meaning it is injected directly into a vein. The dose and rate of administration depend on the specific imaging procedure being performed, the patient's age, weight, and medical history, as well as the imaging equipment being used. Healthcare providers carefully monitor patients during and after the injection to ensure safety and optimal imaging results.
Adverse Reactions: Like other contrast agents, iopromide carries the risk of causing adverse reactions in some patients. Common side effects may include warmth or flushing sensation at the injection site, mild nausea, vomiting, headache, dizziness, and a metallic taste in the mouth. These reactions are usually mild and temporary, resolving on their own without medical intervention.
Allergic Reactions: In rare cases, some individuals may experience allergic reactions to iopromide. These reactions can range from mild to severe and may include itching, hives, rash, difficulty breathing, wheezing, swelling of the face, lips, tongue, or throat (angioedema), and anaphylaxis (a life-threatening allergic reaction). Patients with a history of allergies, asthma, or previous reactions to contrast agents should inform their healthcare provider before undergoing imaging procedures with iopromide.
Renal Toxicity: Contrast-induced nephropathy (CIN) is a potential complication associated with the use of contrast agents like iopromide. CIN refers to a temporary decrease in kidney function that occurs after the administration of contrast media. It is more common in patients with pre-existing kidney disease, diabetes, dehydration, or other risk factors. Healthcare providers may take precautions to minimize the risk of CIN in high-risk patients, such as ensuring adequate hydration and using the lowest possible dose of contrast agent.
Contraindications: Iopromide is contraindicated in patients with a known allergy to the drug or its components, as well as in patients with severe kidney impairment or acute renal failure. It should be used with caution in patients with a history of allergic reactions to other contrast agents, asthma, heart disease, or thyroid disorders.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1 | 1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.3 | 1.33 |
| Allergies | 0.7 | 0.3 | 1.33 |
| Allergy to milk products | 0.4 | -0.4 | |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 1 | 0.6 | 0.67 |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 0.7 | 0.3 | 1.33 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 0.6 | 0.3 | 1 |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.7 | 0.7 | 0 |
| Autism | 1 | 1.6 | -0.6 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.7 | 0.7 | |
| Brain Trauma | 0.3 | 0.3 | |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.3 | 0.2 | 0.5 |
| Carcinoma | 1.3 | 0.4 | 2.25 |
| Celiac Disease | 0.3 | 0.7 | -1.33 |
| Cerebral Palsy | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 0.6 | 0.9 | -0.5 |
| Chronic Kidney Disease | 0.4 | 0.3 | 0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.6 | 0 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.3 | 1.33 |
| Cognitive Function | 0.7 | 0.3 | 1.33 |
| Colorectal Cancer | 1 | 1 | |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 1 | 0.3 | 2.33 |
| Crohn's Disease | 1.6 | 0.7 | 1.29 |
| deep vein thrombosis | 0 | 0.3 | 0 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 1.8 | 0.9 | 1 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.3 | 1 |
| Endometriosis | 0.7 | 0.7 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.6 | 0.4 | 0.5 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.4 | 0.4 | |
| Functional constipation / chronic idiopathic constipation | 0.7 | 0.4 | 0.75 |
| gallstone disease (gsd) | 0.4 | 0.3 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | 0 |
| Generalized anxiety disorder | 0.6 | 0.3 | 1 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.4 | 0.3 | 0.33 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Heart Failure | 0.7 | 0.7 | |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| hyperglycemia | 0.4 | -0.4 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.7 | 0.6 | 0.17 |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 1 | 1 | |
| Inflammatory Bowel Disease | 1 | 1.2 | -0.2 |
| Insomnia | 0.3 | 0.3 | 0 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 0.3 | 0.7 | -1.33 |
| ischemic stroke | 0.7 | 0.7 | |
| Liver Cirrhosis | 1.3 | 0.9 | 0.44 |
| Long COVID | 1 | 1 | 0 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.6 | 1.3 | 0.23 |
| Mood Disorders | 1.8 | 0.9 | 1 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.3 | 1 | 0.3 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.3 | 0.4 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.6 | |
| Obesity | 1.3 | 1.2 | 0.08 |
| obsessive-compulsive disorder | 0.7 | 0.3 | 1.33 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 0.3 | -0.3 | |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 1 | 0.6 | 0.67 |
| Polycystic ovary syndrome | 1.3 | 0.6 | 1.17 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 1 | 0.7 | 0.43 |
| Psoriasis | 0.3 | 0.7 | -1.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.3 | 2.33 |
| Schizophrenia | 1.3 | 0.4 | 2.25 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.7 | 0.4 | 0.75 |
| Sleep Apnea | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.7 | 0.4 | 0.75 |
| Systemic Lupus Erythematosus | 1.3 | 1.3 | |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.6 | 0.3 | 1 |
| Type 2 Diabetes | 1.3 | 1 | 0.3 |
| Ulcerative colitis | 0.7 | 0.7 | 0 |
| Unhealthy Ageing | 0.9 | 0.4 | 1.25 |
| Vitiligo | 0.7 | 0.4 | 0.75 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
